Disease on EC 1.1.1.21 - aldehyde reductase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Direct enzyme assay evidence confirms aldehyde reductase function of Ydr541cp and Ygl039wp from Saccharomyces cerevisiae.
Adenocarcinoma
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Fibrates in the chemical action of daunorubicin.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Oxidation of PAH trans-Dihydrodiols by Human Aldo-Keto Reductase AKR1B10.
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Adenoma
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
aldehyde reductase deficiency
Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
Ascorbic Acid Deficiency
Vitamin C. Biosynthesis, recycling and degradation in mammals.
Astrocytoma
The role of aldehyde reductase AKR1A1 in the metabolism of gamma-hydroxybutyrate in 1321N1 human astrocytoma cells.
Bacterial Infections
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Breast Neoplasms
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Carcinogenesis
A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant.
AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Author's reply to: AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
Glutathione-S-transferase, alcohol dehydrogenase and aldehyde reductase activities during diethylnitrosamine-carcinogenesis in rat liver.
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Oxidation of PAH trans-Dihydrodiols by Human Aldo-Keto Reductase AKR1B10.
Smoking-induced Up-regulation of AKR1B10 Expression in the Airway Epithelium of Healthy Individuals.
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat.
Carcinoma
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers.
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Fibrates in the chemical action of daunorubicin.
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Oxidation of PAH trans-Dihydrodiols by Human Aldo-Keto Reductase AKR1B10.
Regulation of aldo-keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2.
Carcinoma, Adenoid Cystic
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Carcinoma, Basal Cell
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Carcinoma, Ductal
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Carcinoma, Hepatocellular
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Epidermal Growth Factor Induces Tumor Marker AKR1B10 Expression through Activator Protein-1 Signaling in Hepatocellular Carcinoma Cells.
Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Glutathione-S-transferase, alcohol dehydrogenase and aldehyde reductase activities during diethylnitrosamine-carcinogenesis in rat liver.
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Metabolic activation of polycyclic aromatic hydrocarbon trans-dihydrodiols by ubiquitously expressed aldehyde reductase (AKR1A1).
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.
Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants.
Regulation of aldo-keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2.
Role of aldehyde metabolizing enzymes in mediating effects of aldehyde products of lipid peroxidation in liver cells.
Specific differences in gene expression profile revealed by cDNA microarray analysis of glutathione S-transferase placental form (GST-P) immunohistochemically positive rat liver foci and surrounding tissue.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Carcinoma, Squamous Cell
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Fibrates in the chemical action of daunorubicin.
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Cardiomegaly
Identification of a novel aldose reductase-like gene upregulated in the failing heart of cardiomyopathic hamster.
Cataract
Aldo-keto reductases in the eye.
Aldose reductase (EC 1.1.1.21) activity and reduced-glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose.
Diabetic and galactosaemic cataracts.
In vitro expression of rat lens aldose reductase in Escherichia coli.
Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships.
Lens aldehyde reductase and dehydrogenase, and their possible involvement in diabetes and cataract formation.
Cholangiocarcinoma
Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Colitis, Ulcerative
Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice.
Colonic Neoplasms
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo.
Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Colorectal Neoplasms
Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells.
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Altered Expression of Multiple Genes Involved in Retinoic Acid Biosynthesis in Human Colorectal Cancer.
Fibrates in the chemical action of daunorubicin.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Proteomics in human disease: cancer, heart and infectious diseases.
[Downregulation of AKR1B10 gene expression in colorectal cancer]
Dehydration
An aldose reductase homolog from the resurrection plant Xerophyta viscosa Baker.
Diabetes Complications
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Aldo-Keto Reductases 1B in Adrenal Cortex Physiology.
Aldo-keto reductases in the eye.
Aldose and aldehyde reductase in animal tissues.
Aldose reductase and p-crystallin belong to the same protein superfamily as aldehyde reductase.
All in the family.
Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262.
Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus.
Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships.
Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Reductive detoxification of acrolein as a potential role for aldehyde reductase (AKR1A) in mammals.
Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications.
The aldo-keto reductases (AKRs): Overview.
The aldose reductase inhibitor site.
The effect of non-enzymatic glycation on recombinant human aldose reductase.
Diabetes Mellitus
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus.
Diabetes Mellitus, Type 1
AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Diabetic Nephropathies
AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Diabetic Neuropathies
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity.
Endometrial Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Fibrates in the chemical action of daunorubicin.
Fatty Liver
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
Focal Nodular Hyperplasia
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Gastrointestinal Diseases
AKR1B10 in gastrointestinal diseases.
Gastrointestinal Neoplasms
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
Hepatitis
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Hepatitis B, Chronic
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Hepatitis C
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Hepatitis, Chronic
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Herpes Zoster
Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.
Physiological functions and hormonal regulation of mouse vas deferens protein (AKR1B7) in steroidogenic tissues.
Hypernatremia
The role of polyols in cerebral cell volume regulation in hypernatremic and hyponatremic states.
Hyponatremia
The role of polyols in cerebral cell volume regulation in hypernatremic and hyponatremic states.
Idiopathic Pulmonary Fibrosis
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Infection
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Keloid
The aldo-keto reductase AKR1B10 is upregulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease.
Laryngeal Neoplasms
Increased aldehyde reductase expression mediates acquired radioresistance of laryngeal cancer cells via modulating p53.
Leukemia, Myeloid
NADPH-dependent reductases and polyol formation in human leukemia cell lines.
Leukemia, Myeloid, Acute
[Induction of cell differentiation and development of new anticancer drugs]
Liver Diseases
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
Liver Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
[Effects of AKR1B10 gene silence on the growth and gene expression of HCC cell line MHCC97H.].
Lung Neoplasms
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Fibrates in the chemical action of daunorubicin.
Finding Genes Discriminating Smokers from Non-smokers by Applying a Growing Self-organizing Clustering Method to Large Airway Epithelium Cell Microarray Data.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Smoking-induced Up-regulation of AKR1B10 Expression in the Airway Epithelium of Healthy Individuals.
[Transcription TIMP3, DAPk1 and AKR1B10 genes in squamous cell lung cancer]
Metabolic Diseases
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Nasopharyngeal Neoplasms
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasm Metastasis
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasms
ACTH and PRL sensitivity of highly differentiated cell lines obtained by adrenocortical targeted oncogenesis.
Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.
Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells.
AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway.
Aldo-Keto Reductases 1B in Adrenal Cortex Physiology.
Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels.
Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives.
Author's reply to: AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Differential protein expression in honeybee (Apis mellifera L.) larvae: underlying caste differentiation.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Epidermal Growth Factor Induces Tumor Marker AKR1B10 Expression through Activator Protein-1 Signaling in Hepatocellular Carcinoma Cells.
Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Fibrates in the chemical action of daunorubicin.
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
Genetic variation of Aflatoxin B(1) aldehyde reductase genes (AFAR) in human tumour cells.
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Inhibition of human aldose reductase-like protein (AKR1B10) by ?- and ?-mangostins, major components of pericarps of mangosteen.
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.
Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics.
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Quantitative Evaluation of Aldo-keto Reductase Expression in Hepatocellular Carcinoma (HCC) Cell Lines.
Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases.
Regulation of aldo-keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2.
Regulation of aldo-keto-reductase family 1 B10 by 14-3-3? and their prognostic impact of hepatocellular carcinoma.
Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10.
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008.
Structural Determinants of the Selectivity of 3-Benzyluracil-1-acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Substrate Specificity, Inhibitor Selectivity and Structure-Function Relationships of Aldo-Keto Reductase 1B15: A Novel Human Retinaldehyde Reductase.
The aldo-keto reductases (AKRs): Overview.
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity.
[Abnormal expression of genes that regulate retinoid metabolism and signaling in non-small-cell lung cancer].
[Downregulation of AKR1B10 gene expression in colorectal cancer]
[Expression of genes involved in retinoic acid biosynthesis in human gastric cancer].
[Transcription TIMP3, DAPk1 and AKR1B10 genes in squamous cell lung cancer]
Non-alcoholic Fatty Liver Disease
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
Obesity
[Aldehyde reductase activity and blood aldo-keto reductase spectrum in adolescents with neuroendocrine obesity].
Pancreatic Neoplasms
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.
Precancerous Conditions
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Sarcoma, Experimental
Purification and properties of aldose reductase and aldehyde reductase from EHS tumor cells.
Skin Diseases
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Small Cell Lung Carcinoma
Smoking-induced Up-regulation of AKR1B10 Expression in the Airway Epithelium of Healthy Individuals.
Stomach Neoplasms
Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
AKR1B10, a good prognostic indicator in gastric cancer.
Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early-stage gastric cancer.
[Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Urinary Bladder Neoplasms
Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.
Uterine Cervical Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Fibrates in the chemical action of daunorubicin.
Uterine Diseases
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases.
Uterine Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Fibrates in the chemical action of daunorubicin.
Virus Diseases
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.